May 17, 2022 @ 12:30 pm 12:50 pm PDT

Presenter: Paul Ford MD, PhD
Senior VP, Clinical Development
United Kingdom

Please join us to hear about the upcoming ELEVATE IPF Study on Tuesday, May 17th at 12:30 pm – 12:50 pm in Guru Bar 1 or at 1:30 pm – 1:50 pm in Guru Bar 3.

ELEVATE IPF Study is a Randomized Double-blind, Four-Arm Active and Placebo-controlled Dose-Finding Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF).The primary aim is to evaluate safety, tolerability and efficacy of two different doses of LYT-100 compared to pirfenidone or placebo in adults with IPF.

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. For more information, visit www.puretechhealth.com.

Email / Contact Information: [email protected]